TJX:NYSETJX Companies, Inc. (The) Analysis
Data as of 2026-03-09 - not real-time
$158.14
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
TJX is trading at $158.14, comfortably above its 20‑day SMA of 157.46 and 50‑day SMA of 155.48, indicating a short‑term bullish bias. The 200‑day SMA sits at 141.78, providing a long‑term support cushion. Technical momentum is positive, with a bullish MACD crossover (histogram +0.08) and an RSI of 52.7, suggesting room for upside without being overbought. Volume is on an increasing trend, reinforcing the price advance toward the resistance level near $162.68. The stock’s beta of 0.37 and 30‑day volatility of 18.9% point to modest price swings relative to the market. Recent news includes a Baird analyst upgrade to an Outperform rating and a raised price objective of $172, underscoring analyst confidence.
Fundamentally, TJX delivered 8.5% revenue growth, a robust ROE of 59% and free cash flow of $3.94 bn, supporting a dividend yield of 1.07% with a modest 34% payout ratio. However, the DCF fair‑value estimate of $63.8 versus the current price signals the stock is significantly overvalued, and the forward PE of 27.9 remains high for a discount retailer. Insider selling activity adds a slight negative tone, though the dividend appears sustainable. Analyst consensus (18 analysts) rates the stock as a strong‑buy with a median target of $175, implying roughly 8‑9% upside. The company’s off‑price model continues to expand internationally, providing a growth engine beyond the mature U.S. market. Overall, the blend of strong cash generation and modest upside suggests a cautious but positive stance.
Fundamentally, TJX delivered 8.5% revenue growth, a robust ROE of 59% and free cash flow of $3.94 bn, supporting a dividend yield of 1.07% with a modest 34% payout ratio. However, the DCF fair‑value estimate of $63.8 versus the current price signals the stock is significantly overvalued, and the forward PE of 27.9 remains high for a discount retailer. Insider selling activity adds a slight negative tone, though the dividend appears sustainable. Analyst consensus (18 analysts) rates the stock as a strong‑buy with a median target of $175, implying roughly 8‑9% upside. The company’s off‑price model continues to expand internationally, providing a growth engine beyond the mature U.S. market. Overall, the blend of strong cash generation and modest upside suggests a cautious but positive stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish technical indicators (MACD, SMA alignment)
- Support level at $150 providing downside cushion
- Upcoming earnings and insider sales add uncertainty
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth and margins
- Robust cash generation supporting dividend
- Analyst price target indicating upside
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Consistent high ROE and cash flow
- Expanding off‑price model internationally
- Dividend yield and low payout ratio
Key Metrics & Analysis
Financial Health
Revenue Growth8.50%
Profit Margin9.10%
P/E Ratio32.4
ROE59.13%
ROA13.29%
Debt/Equity132.38
P/B Ratio17.5
Op. Cash Flow$6.9B
Free Cash Flow$3.9B
Technical Analysis
TrendBullish
RSI52.7
Support$150.27
Resistance$162.68
MA 20$157.46
MA 50$155.48
MA 200$141.78
MACDBullish
VolumeIncreasing
Fear & Greed Index100
Valuation
Fair Value$63.79
Target Price$171.78
Upside/Downside8.62%
GradeOvervalued
TypeGrowth
Dividend Yield1.07%
Risk Assessment
Beta0.37
Volatility18.88%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.